JP2021152002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021152002A5 JP2021152002A5 JP2021052571A JP2021052571A JP2021152002A5 JP 2021152002 A5 JP2021152002 A5 JP 2021152002A5 JP 2021052571 A JP2021052571 A JP 2021052571A JP 2021052571 A JP2021052571 A JP 2021052571A JP 2021152002 A5 JP2021152002 A5 JP 2021152002A5
- Authority
- JP
- Japan
- Prior art keywords
- hour
- administration
- obinutuzumab
- pharmaceutical composition
- cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574297P | 2017-10-19 | 2017-10-19 | |
| US62/574,297 | 2017-10-19 | ||
| JP2019508989A JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Division JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021152002A JP2021152002A (ja) | 2021-09-30 |
| JP2021152002A5 true JP2021152002A5 (enExample) | 2021-12-02 |
| JP7370357B2 JP7370357B2 (ja) | 2023-10-27 |
Family
ID=64362606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Active JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
| JP2021052571A Active JP7370357B2 (ja) | 2017-10-19 | 2021-03-26 | 医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508989A Active JP6860652B2 (ja) | 2017-10-19 | 2018-10-19 | 医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12129304B2 (enExample) |
| EP (2) | EP3697818B1 (enExample) |
| JP (2) | JP6860652B2 (enExample) |
| KR (3) | KR102906969B1 (enExample) |
| CN (2) | CN111212854A (enExample) |
| AU (2) | AU2018303836B2 (enExample) |
| BR (1) | BR112020007731A2 (enExample) |
| CA (1) | CA3079374A1 (enExample) |
| ES (1) | ES3005784T3 (enExample) |
| IL (2) | IL321935A (enExample) |
| MX (2) | MX419643B (enExample) |
| PL (1) | PL3697818T3 (enExample) |
| TW (2) | TWI805630B (enExample) |
| WO (1) | WO2019017499A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3697818B1 (en) * | 2017-10-19 | 2024-11-27 | F. Hoffmann-La Roche AG | Treatment of cd20-positive b-cell lymphoma with obinutuzumab |
| US20240050562A1 (en) * | 2019-10-04 | 2024-02-15 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| EP4404430A4 (en) | 2021-09-17 | 2025-10-29 | Canon Kk | POWER TRANSMISSION DEVICE AND POWER RECEPTION DEVICE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| DK2234600T3 (da) | 2007-12-21 | 2014-09-08 | Hoffmann La Roche | Antistofformulering |
| SI3179992T1 (sl) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| US11149091B2 (en) * | 2015-12-09 | 2021-10-19 | Cedars-Sinai Medical Center | Methods for treating nephrotic syndrome |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| JP6881583B2 (ja) | 2017-07-21 | 2021-06-02 | 横浜ゴム株式会社 | 空気入りタイヤ |
| EP3697818B1 (en) * | 2017-10-19 | 2024-11-27 | F. Hoffmann-La Roche AG | Treatment of cd20-positive b-cell lymphoma with obinutuzumab |
-
2018
- 2018-10-19 EP EP18804720.3A patent/EP3697818B1/en active Active
- 2018-10-19 KR KR1020247035575A patent/KR102906969B1/ko active Active
- 2018-10-19 CN CN201880067120.XA patent/CN111212854A/zh not_active Withdrawn
- 2018-10-19 CA CA3079374A patent/CA3079374A1/en active Pending
- 2018-10-19 JP JP2019508989A patent/JP6860652B2/ja active Active
- 2018-10-19 TW TW107137033A patent/TWI805630B/zh active
- 2018-10-19 KR KR1020207014191A patent/KR102766089B1/ko active Active
- 2018-10-19 IL IL321935A patent/IL321935A/en unknown
- 2018-10-19 EP EP24213649.7A patent/EP4520347A3/en active Pending
- 2018-10-19 ES ES18804720T patent/ES3005784T3/es active Active
- 2018-10-19 AU AU2018303836A patent/AU2018303836B2/en active Active
- 2018-10-19 US US16/756,057 patent/US12129304B2/en active Active
- 2018-10-19 KR KR1020257043253A patent/KR20260011191A/ko active Pending
- 2018-10-19 CN CN202511095071.9A patent/CN120983618A/zh active Pending
- 2018-10-19 TW TW112120572A patent/TWI828593B/zh active
- 2018-10-19 BR BR112020007731-3A patent/BR112020007731A2/pt unknown
- 2018-10-19 PL PL18804720.3T patent/PL3697818T3/pl unknown
- 2018-10-19 WO PCT/JP2018/038924 patent/WO2019017499A2/en not_active Ceased
- 2018-10-19 IL IL273909A patent/IL273909B2/en unknown
- 2018-10-19 MX MX2020003418A patent/MX419643B/es unknown
-
2020
- 2020-07-13 MX MX2024009217A patent/MX2024009217A/es unknown
-
2021
- 2021-03-26 JP JP2021052571A patent/JP7370357B2/ja active Active
-
2024
- 2024-09-23 US US18/893,101 patent/US20250026847A1/en active Pending
-
2025
- 2025-07-15 AU AU2025205481A patent/AU2025205481A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012321110B2 (en) | Combination treatment | |
| JP2021152002A5 (enExample) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP6360438B2 (ja) | 癌の治療 | |
| JP2019517549A5 (enExample) | ||
| JP2019514974A5 (enExample) | ||
| JP2019514858A5 (enExample) | ||
| CN107872975A (zh) | 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合 | |
| JP2018507243A5 (enExample) | ||
| JP2024517194A (ja) | サイケデリック薬の用量を漸増する方法 | |
| Hansen et al. | Express subcutaneous IgG infusions: decreased time of delivery with maintained safety | |
| JP2006513184A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| CN104203232A (zh) | 用于抗肿瘤试剂施用的方法 | |
| JP2018531605A5 (enExample) | ||
| JP2021152002A (ja) | 医薬組成物 | |
| JP2023011549A5 (enExample) | ||
| JP2017502058A5 (enExample) | ||
| Kranke et al. | Management of postoperative nausea and vomiting (PONV) | |
| JP2018522881A5 (enExample) | ||
| Kim et al. | Helicobacter pylori eradication therapy in Korea | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP2005529152A5 (enExample) | ||
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP2019001830A (ja) | 医薬 |